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Abstract
Background: Previous studies of allopurinol and stroke risk have provided contradictory findings, ranging from a
protective effect to an increased risk. Our objective was to assess whether allopurinol use is associated with the risk
of stroke in the elderly.
Methods: We used the 5 % random sample of Medicare beneficiaries from 2006–2012 to study the association of
new allopurinol initiation and incident stroke. We used multivariable-adjusted Cox regression models adjusted for
age, gender, race, Charlson index, and cardio-protective medications (beta-blockers, ACE inhibitors, diuretics, statins)
to calculate hazards ratio (HR) with 95 % confidence intervals (CI). Sensitivity analyses adjusted for coronary artery
disease (CAD) risk factors including hypertension, hyperlipidemia, diabetes, and smoking instead of Charlson index.
Results: Among 28,488 eligible episodes of incident allopurinol, 2,177 ended in incident stroke (7.6 % episodes). In
multivariable-adjusted analyses, allopurinol use was associated with 9 % lower hazard ratio for stoke, 0.91 (95 % CI,
0.83 to 0.99). Compared to no allopurinol use, allopurinol use durations of 181 days to 2 years, 0.88 (95 % CI, 0.78 to
0.99) and >2 years, 0.79 (95 % CI, 0.65 to 0.96) were significantly associated with lower multivariable-adjusted hazard
of stroke. Sensitivity analyses adjusted for CAD risk factors confirmed these findings. In subgroup analyses,
significant associations were noted between allopurinol use and the risk of ischemic stroke, 0.89 (95 % CI, 0.81
to 0.98); associations were not significant for hemorrhagic stroke, 1.01 (95 % CI, 0.79 to 1.29).
Conclusions: Allopurinol use is associated with lower risk of stroke overall, more specifically ischemic stroke. This
association is evident after 6-months of allopurinol use, and the hazard reduction increases with longer duration of
use. Future studies need to examine underlying mechanisms.
Keywords: Allopurinol, Stroke, Elderly, Medicare, Ischemic stroke, Urate-lowering therapy, Hyperuricemia, Age, Race,
Gender
Abbreviations: ACE inhibitor, Angiotensin converting enzyme inhibitor; CAD, Coronary artery disease;
ED, Emergency department; ICD-9-CM, International classification of diseases, ninth revision, common modification
codes; COPD, Chronic obstructive pulmonary disease; NEDS, National ED sample; ULT, Urate-lowering therapy
Background
Stroke is the second leading cause of cardiovascular
mortality worldwide and among the top five causes of
death in the U.S. [1, 2]. In the U.S., 6.4 million people,
2.7 % of the adult population, suffered from stroke, ac-
cording to the 2012 National Health Interview Survey
[3]. Stroke is associated with significant disability, and a
negative impact on function and quality of life [4–7].
The treatment for stroke has rapidly evolved over time,
and outcomes continue to improve [8]. While some of
the disease risk factors for stroke are well known, there
is a relative lack of studies assessing whether certain
commonly used medications can modify the risk of
stroke.
Allopurinol is a urate-lowering therapy (ULT) that is
commonly used for the treatment of hyperuricemia [9, 10].
In addition to its urate-lowering effect related to of the in-
hibition of xanthine oxidase by its active metabolite, oxy-
purinol, recent studies have suggested other mechanisms of
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actions of allopurinol, some dependent and some inde-
pendent of xanthine oxidase inhibition [11–18]. Many of
these effects including improvement of endothelial function
and reduction of oxidative stress [14, 19–23], reduction of
glycosylated hemoglobin [14], and attenuation of intercellu-
lar adhesion molecule-1 levels [24], may potentially lower
the risk of stroke. To our knowledge, it is not known
whether allopurinol use is associated with a lower risk of
stroke.
Previous studies of allopurinol examined a composite car-
diovascular outcome (that included stroke) and provided
contradictory findings, ranging from a protective
effect [25, 26] to an increased risk [27, 28]. These
contradictory findings were related at least partially to
differences in patient populations (renal failure, hyper-
tensive nephropathy, heart failure vs. gout), study de-
sign (randomized vs. observational) and covariates/
confounders adjusted in the analyses. In a 7-year
follow-up of a 2-year randomized trial in patients
with chronic kidney disease, adjusted for race, sex
and renal function, allopurinol use was associated
with lower risk of 0.43 (95 % CI, 0.21 to 0.88) of car-
diovascular events (including CAD, cerebrovascular
disease, heart failure and peripheral vascular disease)
[25]. In an observational study of 187 patients with
hypertensive nephropathy, allopurinol use was associ-
ated with an adjusted hazard of 0.34 (p = 0.04) for
cardiovascular disease (CAD, heart failure and stroke)
[26]. In a study of heart failure patients using Scottish
database, Wei et al. reported that with a minimum
follow-up of 5 years, compared with non-users, allo-
purinol users had a no significant difference in car-
diovascular event (nonfatal myocardial infarction (MI),
nonfatal stroke and cardiovascular mortality), 0.88
(95 % CI, 0.73 to 1.05) [27]. Kok et al. [28] studied >4,000
patients with newly diagnosed gout and no pre-existing
severe form of CVD using a prevalent user design and
reported that allopurinol use was associated with an in-
creased adjusted hazard of 1.25 for cardiovascular event
(hospitalization for MI, stroke, hypertension etc.).
None of the previous studies examined the association
of allopurinol with stroke as an outcome in the general
population. Therefore, findings can only be generalized
to patient sub-populations with hypertensive nephropa-
thy, renal failure, gout or heart failure, and then only to
a cardiovascular composite outcome, that includes per-
ipheral vascular disease, heart failure, MI, angina etc. in
addition to stroke. Thus, well-designed studies examin-
ing the effect of allopurinol use on the risk of stroke are
needed, especially for adults 65 years and older. This is
important since 2/3rd of patients with stroke in the U.S.
are adults 65 years and older [29]. Therefore, our object-
ive was to assess whether incident allopurinol use was
independently associated with a reduction in the risk of
incident stroke in the elderly, using a population-based
approach. We hypothesized that allopurinol use and its
duration of use will each be independently associated
with a reduction in the risk of incident stroke in adults
65 years and older. In exploratory analyses, we examined
whether stroke risk reduction with allopurinol varied by
age, gender and race.
Methods
Study cohort and population of interest
We conducted a retrospective cohort study using the 5 %
random sample of Medicare beneficiary claims from 2006
to 2012. These data were obtained from the Centers for
Medicare and Medicaid Services (CMS) Chronic Condi-
tion Data Warehouse and included beneficiaries’ demo-
graphic information and insurance claims (inpatient,
outpatient, skilled nursing facility, non-institutional pro-
vider, home health, hospice, durable medical equipment
and prescription drugs).
Study eligibility criteria were: (1) Medicare beneficiar-
ies who were 65 years of age or older and lived in the
U.S.; (2) continuous enrollment in traditional Medicare
fee-for-service and pharmacy coverage (Parts A, B and
D) and non-enrollment in Medicare Advantage Plan;
and (3) new treatment with allopurinol (defined below).
The Institutional Review Board at the University of
Alabama at Birmingham approved the study, and waived
the need for patient informed consent for this database
study. All investigations were conducted in conformity
with ethical principles of research.
Exposure definition and covariates
Incident allopurinol use, i.e. new allopurinol use, was de-
fined as a new filled allopurinol prescription, with no
allopurinol prescription filled during a look-back base-
line period of 365 days. Each day of observation within
each episode was labeled as allopurinol exposed or non-
exposed based upon the days’ supply for allopurinol pre-
scription in pharmacy records after the beginning of
allopurinol treatment episode. We allowed up to 30 days
stock carry over. Patients were considered exposed for
30 days after the end of days’ supply to capture events
attributable to allopurinol, after which a new continuous
allopurinol exposure period started. Allopurinol use dur-
ation was categorized as none, 1 to 180 days, 181 days
to 2 years, and longer than 2 years, based on clinical
relevance and current use patterns of allopurinol [9, 10].
A patient could contribute multiple allopurinol treat-
ment episodes during different time periods.
We obtained the following covariates in the baseline
period for each allopurinol treatment episode from the
Medicare denominator file: age, gender, race/ethnicity, resi-
dence (Northeast, South, Midwest, West) and comorbidity
scores, derived using Charlson-Romano comorbidity index
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score, a validated score for comorbidity assessment consist-
ing of common medical comorbidities [30], adapted for
claims data by Romano et al.. Comorbidities included in
Charlson-Romano comorbidity index were: myocardial in-
farction, congestive heart failure, cerebrovascular disease,
dementia, chronic pulmonary disease, connective tissue dis-
ease, peptic ulcer disease, mild liver disease, diabetes with-
out complications, diabetes with complications, paraplegia
and hemiplegia, renal disease, cancer, moderate to severe
liver disease, metastatic cancer and AIDS/HIV [31].
Charlson-Romano index score is a valid comorbidity
measure [32, 33].
Study outcome
Incident stroke was our study outcome of interest, de-
fined as the first occurence of stroke during the study
period after the initiation of a new allopurinol prescrip-
tion. Incident stroke was identified by the presence of
International Classification of Diseases, ninth revision,
common modification (ICD-9-CM) codes for stroke
(430.xx, 431.xx, 433.x1, 436.xx, 434.xx, except 434.x0);
subgroup analyses were for hemorrhagic stroke (430.xx,
431.xx) and ischemic stroke (rest of the codes). This ap-
proach using ICD-9-CM codes is accurate for identifica-
tion of cases and risk factors, and has high positive
predictive value, usually exceeding >90 % [34–36]. The
earliest allopurinol treatment initiation date during the
study period marked the beginning of the follow-up for
each treatment episode that ended on the earliest of first
date of stroke, losing full Medicare coverage, the date of
death, or the end of the study (12/31/12).
Statistical analyses
We calculated descriptive statistics by the occurrence of
stroke among allopurinol users and by allopurinol expos-
ure among episodes with stroke. The main analysis fo-
cused on stroke (including all subtypes). We performed
Cox proportional hazard regression models to assess the
association between allopurinol exposure or duration of
allopurinol use and incident stroke. Multivariable analysis
were adjusted for age, gender, race and Charlson-Romano
comorbidity score. We accounted for correlated episodes
using the Huber-White “Sandwich” variance estimator
and calculated robust standard errors for all estimates,
since patients could possibly contribute more than one
episode of new allopurinol use. We performed sensitivity
analyses using Cox proportional hazard regression models
to assess these associations by replacing Charlson-
Romano index score with selected comorbidities, includ-
ing risk factors for coronary artery disease (CAD) in one
model, and replacing with peripheral vascular disease
(PVD) and CAD in another separate model. We calculated
hazard ratio (HR) and 95 % confidence intervals (CI). We
also performed subgroup analyses by assessing the rela-
tionship of allopurinol use and allopurinol use duration to
each type of stroke, ischemic vs. hemorrhagic stroke.
Table 1 Demographic and clinical characteristics of episodes of incidenta allopurinol use
All Incident stroke during follow up P-value
No Yes
Total, N (episodes) 28,488 26,311 2,177
Age 76.5 (7.4) 76.4 (7.4) 78.1 (7.3) <0.0001
Gender, N (%) <0.0001
Male 14,163 (49.7) 13,185 (50.1) 978 (44.9)
Female 14,325 (50.3) 13,126 (49.9) 1,199 (55.1)
Race/Ethnicity, N (%) 0.0004
White 22,627 (79.4) 20,970 (79.7) 1,657 (76.1)
Black 3,371 (11.8) 3,049 (11.6) 322 (14.8)
Hispanic 589 (2.1) 538 (2.0) 51 (2.3)
Asian 1,236 (4.3) 1,134 (4.3) 102 (4.7)
Native American 92 (0.3) 83 (0.3) 9 (0.4)
Other/unknown 573 (2.0) 537 (2.0) 36 (1.7)
Region, N (%) 0.013
Northeast 4,586 (16.6) 4,224 (16.6) 362 (17.3)
Midwest 6,400 (23.2) 5,958 (23.3) 442 (21.1)
South 11,405 (41.3) 10,486 (41.1) 919 (44.0)
West 5,227 (18.9) 4,859 (19.0) 368 (17.6)
Charlson- Romano comorbidity Index Score 3.61 (3.22) 3.56 (3.20) 4.27 (3.39) <0.0001
aNo allopurinol use in the baseline period of 365 days
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Results
Study population characteristics
There were a total of 28,488 episodes of incident allopur-
inol use (Table 1). Of these, 2,177 allopurinol use episodes
were associated with incident stroke (7.6 % episodes; base-
line period of 365 days without any stroke), while the ma-
jority did not (Fig. 1). Compared to incident allopurinol
use without stroke, those with episodes of incident stroke
on allopurinol were older, more likely to be women or
white, and had higher Charlson index score (4.27 vs. 3.56);
some differences were noted by region of residence
(Table 1). Mean (median) length to first stroke event was
437 (median, 299) days and mean (median) follow-up time
was 704 (median, 579) days.
Table 2 shows the crude incidence rate of stroke by
allopurinol exposure. Crude incidence rates of stroke
with and without allopurinol exposure were similar. Du-
rations of allopurinol use longer than 6-month were
associated with lower crude incidence rate of stroke
compared to no allopurinol use (Table 2).
Allopurinol and the risk of incident stroke
Compared to non-use, age and Charlson comorbidity
index were higher with allopurinol use for episodes with
Number of beneficiaries in 2006-2012 Medicare 5% sample 
Nb= 3,316,624
No prescriptions for allopurinol use in 06-12   
Nb=3,204,341
Beneficiaries with 1+ allopurinol prescription filled (TE) in 06-12
Nb= 112,283 Np=1,841,849
Lost A+B+D-HMO coverage in TE -365d
Np = 45,394, Nb= 42,861
Episodes where allopurinol prescription fill in preceded by 365 d without allopurinol 
(service date after Jan 01, 2007), Np = 90526, Nb =83892
Allopurinol new prescriptions, NE = 30,063, Nb=28,058
Not 5% sample in TE -365d, Np= 8630, Nb= 8609
Not lived in 50 states or DC at TE, Np =64, Nb =56
Have two birth dates or death dates (from 06 – 12) 
Np= 80, Nb = 78
Number of episodes with no CVA during baseline period (365 days before index date), 
NE=28,488, Nb= 26,627 (147 beneficiaries are in both the following categories)
Final allopurinol exposure episodes, NE =30,061, Nb=28,056 (after censoring)     
(Two episodes excluded as service date later than death date)                               
Age not eligible, Np = 5,809, Nb = 5,416
Number of episodes with CVA
during follow up
NE = 2,177, Nb = 2,168
Number of episodes with No CVA
during follow up
NE = 26,311, Nb = 24,606
Number of episodes with CVA with 
allopurinol exposure
NE = 1334, Nb = 1332
Number of episodes with CVA with no 
allopurinol exposure
NE = 843, Nb =839
Fig. 1 Flow-chart of study cohort of incident allopurinol users from 2006–2012 for baseline of 365 days. Legend: NE, number of episodes; Nb,
number of beneficiaries; Np, number of prescriptions
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incident stroke (Table 3). In multivariable-adjusted ana-
lyses, allopurinol use was associated with 9 % lower hazard
ratio for stoke, 0.91 (95 % CI, 0.83 to 0.99). Age 75- < 85
and ≥85, black race, higher Charlson-Romano index score
and the use of beta-blockers were associated with higher
hazards of incident stroke (Table 4). Specific hazards ra-
tios by age, gender and race are shown in Additional file 1:
Table S1.
We found that compared to no allopurinol use, allo-
purinol use durations of longer than 6-months were
each associated with lower multivariable-adjusted hazard
ratios for stroke: 181 days to 2 years, 0.88 (95 % CI, 0.78
to 0.99) and >2 years, 0.79 (95 % CI, 0.65 to 0.96)
(Table 4).
Sensitivity analyses were performed adjusting for dia-
betes, hypertension, hyperlipidemia and tobacco use dis-
order as CAD risk factors, peripheral vascular disease and
CAD confirmed the findings for both allopurinol use and
the duration of allopurinol use (Additional file 2: Table S2).
Subgroup analyses for allopurinol use duration and by
the type of stroke
In multivariable-adjusted subgroup analyses, allopurinol
use durations of 181 days to 2 years and >2 years were
associated with a reduction of hazard of stroke (Table 4),
most evident for the age group 75–84, female gender
and patients who were white (Fig. 2).
In multivariable-adjusted subgroup analyses, we found
no significant association of allopurinol use or duration of
allopurinol use with the risk of hemorrhagic stroke
(Additional file 3: Table S3). On the other hand, significant
associations were noted between allopurinol use and the
risk of ischemic stroke, similar in magnitude to overall in-
cident stroke analyses (Additional file 3: Table S3).
Discussion
We used an incident/new user design (new users of allo-
purinol indicated by a new allopurinol filled prescrip-
tions) and a population-based approach to examine the
effect of allopurinol use on the risk of stroke in the U.S.
elderly. We controlled for patient demographics, comor-
bidity and use of cardio-protective medications to
understand whether the association of allopurinol was
independent of other CAD risk factors and treatments.
This new knowledge is important, since the majority of
strokes occur in adult Americans 65 years and older
[29]. Subgroup analyses examined whether association of
allopurinol was evident for separate analyses for ische-
mic and hemorrhagic stroke. Several study findings
merit further discussion.
Our finding of independent association of incident allo-
purinol use with a reduction of hazard of incident stroke
in the older adults compared to no allopurinol use, is
novel. We are unaware of other studies that have exam-
ined this specific question. Most previous studies in this
area of research had several limitations in that: (1) all
studied a composite cardiovascular outcome that included
heart failure, angina, MI etc. in addition to stroke [25–28];
(2) most used prevalent user design [26, 28]; and (3) all
studies were in patient subpopulations with limited
generalizability [25–28]. Composite outcome assessment
did not allow the interpretation regarding the risk of
stroke, due to inclusion of related outcomes, which might
have different mechanisms than stroke, i.e., heart failure,
angina etc. It is therefore not surprising that findings
Table 3 Demographic and comorbidity characteristics of
episodes that ended in stroke by allopurinol use







Age 77.5 (7.1) 78.5 (7.4) 0.003
Gender 0.95
Male 378 (44.8) 600 (45.0)
Female 465 (55.2) 734 (55.0)
Race 0.54
White 632 (75.0) 1,025 (76.8)
Black 128 (15.2) 194 (14.5)
Others 83 (9.9) 115 (8.6)
Charlson-Romano
Index Score
3.99 (3.27) 4.44 (3.44) 0.002
Specific Comorbidities
Diabetes 382 (45.3) 641 (48.1) 0.21
Hypertension 724 (85.9) 1,174 (88.0) 0.15
Cardiovascular Disease 128 (15.2) 232 (17.4) 0.18
Peripheral Vascular Disease 187 (22.2) 302 (22.6) 0.80
Hyperlipidemia 591 (70.1) 970 (72.7) 0.19
NE number of episodes
Table 2 Crude incidence rate of CVA with allopurinol exposure





Crude Stroke Incidence Rate
per 1,000,000 person-days
Allopurinol Exposurea
Yes 12,900,000 1,334 108
No 7,902,385 843 106
Allopurinol use duration
None 7,902,385 843 106




> 2 years 1,721,507 130 76
aAllopurinol exposure was defined as up to 30 days after last day of
allopurinol prescription fill or refill to capture the biologic effect of
allopurinol use
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ranged from a reduced risk of with allopurinol [25, 26] to
an increased risk of composite cardiovascular outcome
that included stroke [27, 28].
The stroke risk reduction associated with allopurinol
use noted in our study and others may be related to sev-
eral potential mechanisms. Allopurinol use was associ-
ated with attenuation of intercellular adhesion molecule-
1 levels in patients after a recent stroke [24]. Allopurinol
use improved endothelial function and reduction of oxi-
dative stress [14, 19–23] and reduced glycosylated
hemoglobin [14]. Allopurinol reduced serum urate, and
an elevated serum urate was associated with higher
levels of chronic inflammatory markers in cardiac dis-
ease [37].
Regardless of the mechanism of action, the significant
reduction of stroke risk associated with allopurinol has
practical implications. The hazards of stroke were reduced
by 9 % for allopurinol use vs. non-use and reduced by 12–
21 % with longer allopurinol use durations. Thus, the
magnitudes of hazard reduction were moderate, not large.
Allopurinol is commonly used for the treatment of gout
and reduced morbidity related to joint inflammation and
pain, including disability, functional limitation and joint
destruction. The potential added benefit of stroke reduc-
tion with allopurinol should be shared with patients with
gout at the time of allopurinol treatment initiation. This
discussion should impact the overall risk/benefit ratio of
allopurinol, as well as serve as a motivating factor for im-
proving allopurinol adherence and persistence, which is
low for allopurinol in the first year after initiation [38].
More evidence is needed before an informed benefit/risk
analysis of allopurinol use can be shared with patients
with asymptomatic hyperuricemia without gout, where
allopurinol use is currently not recommended [39].
Maximum hazard reduction in incident stroke with allo-
purinol use occurred in the >6 to 24 months and >2 years
after new allopurinol use, with 12 % and 21 % hazard
reduction, respectively. We noted an incremental
stroke risk reduction associated with longer duration
of allopurinol use. This important finding indicates
Table 4 Association of risk factors with incident strokea in patients who received allopurinol
Univariate Multivariable-adjusted (model 1)* Multivariable-adjusted (model 2)**
HR (95 % CI) P-value HR (95 % CI) P-value HR (95 % CI) P-value
Age
65- <75 Ref Ref Ref
75- <85 1.63 (1.48, 1.79) <0.0001 1.54 (1.40, 1.70) <0.0001 1.54 (1.40, 1.70) <0.0001
≥ 85 2.09 (1.86, 2.35) <0.0001 1.91 (1.69, 2.15) <0.0001 1.91 (1.69, 2.16) <0.0001
Gender
Male Ref Ref Ref
Female 1.21 (1.12, 1.32) <0.0001 1.09 (1.00, 1.19) 0.05 1.09 (1.00, 1.19) 0.05
Race
White Ref Ref Ref
Black 1.40 (1.24, 1.57) <0.0001 1.37 (1.21, 1.54) <0.0001 1.36 (1.21, 1.53) <0.0001
Other 1.09 (0.94, 1.26) 0.27 1.09 (0.94, 1.27) 0.23 1.09 (0.94, 1.26) 0.26
Charlson- Romano score 1.11 (1.10, 1.12) <0.0001 1.10 (1.09, 1.11) <0.0001 1.10 (1.09, 1.11) <0.0001
Cardiovascular drug use (Ref, no use)
Statins 0.93 (0.75, 1.15) 0.49 0.91 (0.73, 1.13) 0.39 0.91 (0.73, 1.13) 0.38
Beta blockers 1.38 (1.15, 1.67) 0.0007 1.40 (1.15, 1.70) 0.0008 1.40 (1.15, 1.70) 0.0008
Diuretics 1.05 (0.86, 1.27) 0.63 0.97 (0.79, 1.18) 0.74 0.96 (0.79, 1.18) 0.72
ACE inhibitor 0.92 (0.73, 1.18) 0.52 0.97 (0.76, 1.24) 0.78 0.97 (0.76, 1.23) 0.78
Allopurinol use (Ref, none) 0.92 (0.84, 1.01) 0.07 0.91 (0.83, 0.99) 0.04 - -
Allopurinol use duration
None Ref Ref
1 - 180 days 1.02 (0.89, 1.15) 0.81 1.00 (0.88, 1.14) 0.97
181 days - 2 years 0.90 (0.80, 1.01) 0.07 0.88 (0.78, 0.99) 0.03
> 2 years 0.78 (0.64, 0.96) 0.02 0.79 (0.65, 0.96) 0.02
* Model 1 = Allopurinol use + age + race + gender + Charlson score + beta blockers + diuretics + ACE inhibitors + Statins
** Model 2 = Allopurinol use duration + age + race + gender + Charlson score + beta blockers + diuretics + ACE inhibitors + Statins
aNo stroke within the baseline period of 365 days before the index date of allopurinol episode
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that allopurinol use is needed for >6 months to ex-
perience this potential benefit.
In exploratory multivariable-adjusted subgroup analyses,
allopurinol use durations of 181 days to 2 years and >2 years
were associated with a reduction of hazard of stroke, most
evident for the age group 75–84, female gender and people
who were white. Our study identified the sub- groups of pa-
tients likely to benefit the most with longer durations of
allopurinol use. These findings need to be confirmed in fu-
ture studies.
Our exploratory analyses added further clarity to this pro-
tective effect of allopurinol. Risk reduction associated with
allopurinol use was noted for ischemic stroke, but not
hemorrhagic stroke. These two types of stroke differ quite a
bit in pathophysiology and outcomes [40]. It was reassuring
that the protection for overall stroke risk is primarily due to
protection against ischemic stroke, which is consistent with
allopurinol’s effect on oxidative stress, endothelial function
and chronic inflammation [14, 19–23, 37].
Our study has several strengths and limitations. The
diagnoses of CAD risk factors and Charlson-Romano
index were based on the presence of ICD-9-CM codes,
which may have led to misclassification bias. However, the
codes for outcomes and covariates have reasonable accur-
acy [34–36], and the use of ICD-9-CM codes for
Charlson-Romano index is a standard valid approach that
is used commonly in analyses of large claims databases,
such as Medicare. The observational study design does
not allow us to eliminate confounder bias, due to unmeas-
ured confounding; however, we included important demo-
graphic, clinical, risk factors and cardiac medications to
account for important potential confounders. Serum urate
levels were available for a small proportion of patients and
therefore we could not examine whether the associations
we noted were mediated through the reduction of serum
urate or not. The database also did not allow us to include
other variables such body mass index, diet and exercise,
which might be potential risk factors for stroke.
The contribution of healthy adherer effect can not be
ruled out, since patients adherent to/using allopurinol may
have other healthy behaviors, such as high adherence to
preventive care, other medications, healthier lifestyle etc.,
which may all reduce the risk of stroke etc. A filled pre-
scription is a surrogate for, but can not be equated to the
actual use of allopurinol. Since study’s eligibility criteria in-
cluded that patients to have continued coverage, these find-
ings are likely not applicable to elderly who loose Medicare
coverage. Whether these findings can be generalized to
populations other than adults 65 years and older is not
known, and further study is needed in this area.
Study strengths include a large sample size, the use of a
sample that allows generalizable findings to Medicare
enrollees, inclusion of MI/stroke risk factors in analyses to
avoid confounding bias, and the robustness of estimates in
sensitivity analyses. Implementation of new user design (i.e.,
examining only new users of allopurinol) in our study
avoids over-adjustment for factors on the causal pathway,









































































































































Fig. 2 Multivariable-adjusted* Hazard ratios of duration of allopurinol
use with incident stroke by age (2a), gender (2b) and race (2c). Legend:
*For the multivariable-adjusted subgroup analyses by age, gender and
race, the main model was adjusted for all factors (age, gender, race
and Charlson-Romano comrobidity score) except the factor of interest,
respectively, which was used to perform stratified analysis (age, gender,
race). We found that several subgroups had statistically significantly
reduced hazard with allopurinol use, namely: Age group 65–75 years,
181 days to 2 years; Age group 75–84 years, >2 years; female gender,
181 days to 2 years; White race, 181 days to 2 years and >2 years. As
expected, most of the subgroups had very few events, and therefore
most subgroup analyses did not have power to detect significant
differences within each subgroup
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Conclusions
In conclusion, we found that allopurinol use was inde-
pendently associated with a lower risk of incident stroke
in older Americans. Allopurinol use for 6 months to
2 years and >2 years were associated with a lower risk of
incident stroke. The stroke risk reduction associated
with allopurinol was seen in the subgroup analysis for
ischemic stroke, but not hemorrhagic stroke. Future
studies need to explore the factors that mediate this
potentially protective effect, and assess whether these
factors are dependent or independent of serum urate re-
ductions and anti-oxidant effects seen with allopurinol.
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